Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited.Materials and methods: This was a dual-cent...

Full description

Bibliographic Details
Main Authors: Hong-Shuai Li, Guang-Jian Yang, Yi Cai, Jun-Ling Li, Hai-Yan Xu, Tao Zhang, Li-Qiang Zhou, Yu-Ying Wang, Jin-Liang Wang, Xing-Sheng Hu, Xiang Yan, Yan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
dacomitinib
non-small cell lung cancer
major uncommon EGFR mutations
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.919652/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.919652/full

Similar Items